Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Lyell Immunopharma Inc (LYEL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$15.00-2.79%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LYEL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash sufficiency into Q3 2027 | It aims to maintain cash sufficiency into Q3 2027. | Intact | Cash sufficiency falls short of meeting needs into Q3 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development investment, not an established earnings compounder. The long-term thesis is intact, with management’s lead-trial timeline on track, but losses and elevated risk make the evidence base limited.
The valuation evidence points to an expensive setup, while the expectations gap is positive, suggesting the market’s assumptions may not fully match the business evidence. The snapshot calls this pricing fragile only because of valuation, not because expensive valuation is combined with weak fundamentals and turbulence.
Near term, results may remain uneven: LYEL had two recent earnings beats after a miss, but recent earnings surprises are erratic and the estimated chance of a miss is elevated. Over the multi-year view, ronde-cel’s pivotal trial is on track, with data expected in mid-2027 and a BLA submission planned for the second half of 2027; cash declined in Q2, though management says it can fund operations into Q3 2027.
The central swing factor is whether LYEL delivers the planned trial milestones, including progress updates for PiNACLE-H2H and continued development of LYL273. Near-term, a guidance cut or further labor-market weakness could weigh on the outlook, while continued strength from major Healthcare companies could support the sector backdrop.
For the next 1 to 3 years, the thesis rests on clinical progress and managing cash through a loss-making period; valuation is expensive, and execution risk remains elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Lyell Immunopharma Inc's published investment case. The stated target is Smooth CFO transition with positive operational progress. |
| Improving |
| Leadership instability or failure to execute key milestones |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stabilize and grow revenue beyond FY26 | A primary condition in Lyell Immunopharma Inc's published investment case. The stated target is Revenue growth above -60% next year, aiming for stabilization or improvement. | Broken | Revenue decline worsens beyond -60% in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-7.99 → $-7.59 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-7.99 | $9,437,366 | 5 / 6 |
| 2026-07-25 | $-7.99 | $9,437,366 | 5 / 6 |
| 2026-07-26 | $-7.86 | $7,864,472 | 6 / 6 |
| 2026-07-27 | $-7.86 | $7,864,472 | 6 / 6 |
| 2026-07-28 | $-7.86 | $6,740,980 | 8 / 7 |
| 2026-07-29 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-07-30 | $-7.86 | $6,740,980 | 8 / 7 |
| 2026-07-31 | $-7.86 | $6,740,980 | 8 / 7 |
| 2026-08-01 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-02 | $-7.86 | $6,740,980 | 8 / 7 |
| 2026-08-03 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-04 | $-7.86 | $6,740,980 | 8 / 7 |
| 2026-08-05 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-06 | $-7.86 | $6,740,980 | 8 / 7 |
| 2026-08-07 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-08 | $-6.20 | $6,740,980 | 1 / 7 |
| 2026-08-09 | $-6.20 | $6,740,980 | 1 / 7 |
| 2026-08-10 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-12 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-13 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-14 | $-7.86 | $7,864,472 | 6 / 7 |
| 2026-08-15 | $-7.86 | $7,864,472 | 4 / 6 |
| 2026-08-16 | $-7.86 | $7,864,472 | 4 / 6 |
| 2026-08-17 | $-7.86 | $7,864,472 | 4 / 6 |
| 2026-08-18 | $-7.86 | $7,864,472 | 4 / 7 |
| 2026-08-19 | $-7.86 | $7,864,472 | 4 / 7 |
| 2026-08-20 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-21 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-22 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-23 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-24 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-25 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-26 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-27 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-28 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-29 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-30 | $-7.63 | $11,286 | 4 / 8 |
| 2026-08-31 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-01 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-02 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-03 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-04 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-05 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-06 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-07 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-08 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-09 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-10 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-11 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-12 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-13 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-14 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-15 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-16 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-17 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-18 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-19 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-20 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-21 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-22 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-23 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-24 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-25 | $-7.63 | $11,286 | 4 / 8 |
| 2026-09-26 | $-7.59 | $13,167 | 4 / 8 |
| 2026-09-27 | $-7.59 | $13,167 | 4 / 8 |
| 2026-09-28 | $-7.59 | $13,167 | 4 / 8 |
| 2026-09-29 | $-7.59 | $13,167 | 4 / 8 |
| 2026-09-30 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-01 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-02 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-03 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-04 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-05 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-06 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-07 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-08 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-09 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-10 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-11 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-12 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-13 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-14 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-15 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-16 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-17 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-18 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-19 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-20 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-21 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-22 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-23 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-24 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-25 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-26 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-27 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-28 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-29 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-30 | $-7.59 | $13,167 | 4 / 8 |
| 2026-10-31 | $-7.59 | $13,167 | 4 / 8 |
| 2026-11-01 | $-7.59 | $13,167 | 4 / 8 |
| 2026-11-02 | $-7.59 | $13,167 | 4 / 8 |
| 2026-11-03 | $-7.59 | $13,167 | 4 / 8 |
| 2026-11-04 | $-7.59 | $6,500 | 4 / 8 |
| 2026-11-05 | $-7.59 | $6,500 | 4 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.